ID G3VW24_SARHA Unreviewed; 742 AA.
AC G3VW24;
DT 16-NOV-2011, integrated into UniProtKB/TrEMBL.
DT 07-APR-2021, sequence version 2.
DT 27-MAR-2024, entry version 64.
DE SubName: Full=NFKB inhibitor zeta {ECO:0000313|Ensembl:ENSSHAP00000007379.2};
GN Name=NFKBIZ {ECO:0000313|Ensembl:ENSSHAP00000007379.2};
OS Sarcophilus harrisii (Tasmanian devil) (Sarcophilus laniarius).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Metatheria; Dasyuromorphia; Dasyuridae; Sarcophilus.
OX NCBI_TaxID=9305 {ECO:0000313|Ensembl:ENSSHAP00000007379.2, ECO:0000313|Proteomes:UP000007648};
RN [1] {ECO:0000313|Ensembl:ENSSHAP00000007379.2, ECO:0000313|Proteomes:UP000007648}
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=21709235; DOI=10.1073/pnas.1102838108;
RA Miller W., Hayes V.M., Ratan A., Petersen D.C., Wittekindt N.E., Miller J.,
RA Walenz B., Knight J., Qi J., Zhao F., Wang Q., Bedoya-Reina O.C.,
RA Katiyar N., Tomsho L.P., Kasson L.M., Hardie R.A., Woodbridge P.,
RA Tindall E.A., Bertelsen M.F., Dixon D., Pyecroft S., Helgen K.M.,
RA Lesk A.M., Pringle T.H., Patterson N., Zhang Y., Kreiss A., Woods G.M.,
RA Jones M.E., Schuster S.C.;
RT "Genetic diversity and population structure of the endangered marsupial
RT Sarcophilus harrisii (Tasmanian devil).";
RL Proc. Natl. Acad. Sci. U.S.A. 108:12348-12353(2011).
RN [2] {ECO:0000313|Ensembl:ENSSHAP00000007379.2}
RP IDENTIFICATION.
RG Ensembl;
RL Submitted (NOV-2023) to UniProtKB.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR AlphaFoldDB; G3VW24; -.
DR STRING; 9305.ENSSHAP00000007379; -.
DR Ensembl; ENSSHAT00000007441.2; ENSSHAP00000007379.2; ENSSHAG00000006414.2.
DR eggNOG; KOG0504; Eukaryota.
DR GeneTree; ENSGT00940000153695; -.
DR HOGENOM; CLU_030240_0_0_1; -.
DR InParanoid; G3VW24; -.
DR TreeFam; TF330224; -.
DR Proteomes; UP000007648; Unassembled WGS sequence.
DR GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IEA:Ensembl.
DR GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
DR GO; GO:0070974; F:POU domain binding; IEA:InterPro.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR GO; GO:0003712; F:transcription coregulator activity; IEA:Ensembl.
DR GO; GO:0042100; P:B cell proliferation; IEA:Ensembl.
DR GO; GO:1990117; P:B cell receptor apoptotic signaling pathway; IEA:Ensembl.
DR GO; GO:0097398; P:cellular response to interleukin-17; IEA:Ensembl.
DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR GO; GO:0002544; P:chronic inflammatory response; IEA:Ensembl.
DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl.
DR GO; GO:0050829; P:defense response to Gram-negative bacterium; IEA:Ensembl.
DR GO; GO:1904019; P:epithelial cell apoptotic process; IEA:Ensembl.
DR GO; GO:0061436; P:establishment of skin barrier; IEA:Ensembl.
DR GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl.
DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR GO; GO:0090594; P:inflammatory response to wounding; IEA:Ensembl.
DR GO; GO:0045190; P:isotype switching; IEA:Ensembl.
DR GO; GO:0032980; P:keratinocyte activation; IEA:Ensembl.
DR GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR GO; GO:0043616; P:keratinocyte proliferation; IEA:Ensembl.
DR GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IEA:Ensembl.
DR GO; GO:0002317; P:plasma cell differentiation; IEA:Ensembl.
DR GO; GO:0050729; P:positive regulation of inflammatory response; IEA:Ensembl.
DR GO; GO:2000321; P:positive regulation of T-helper 17 cell differentiation; IEA:Ensembl.
DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR GO; GO:0072718; P:response to cisplatin; IEA:Ensembl.
DR GO; GO:0051593; P:response to folic acid; IEA:Ensembl.
DR GO; GO:0140459; P:response to Gram-positive bacterium; IEA:Ensembl.
DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR GO; GO:0002456; P:T cell mediated immunity; IEA:Ensembl.
DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl.
DR GO; GO:0045063; P:T-helper 1 cell differentiation; IEA:Ensembl.
DR GO; GO:0072539; P:T-helper 17 cell differentiation; IEA:Ensembl.
DR GO; GO:0002224; P:toll-like receptor signaling pathway; IEA:Ensembl.
DR GO; GO:0070897; P:transcription preinitiation complex assembly; IEA:Ensembl.
DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR InterPro; IPR002110; Ankyrin_rpt.
DR InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR InterPro; IPR047571; OCA.
DR PANTHER; PTHR24124; ANKYRIN REPEAT FAMILY A; 1.
DR PANTHER; PTHR24124:SF5; NF-KAPPA-B INHIBITOR ZETA; 1.
DR Pfam; PF12796; Ank_2; 2.
DR PRINTS; PR01415; ANKYRIN.
DR SMART; SM00248; ANK; 6.
DR SUPFAM; SSF48403; Ankyrin repeat; 1.
DR PROSITE; PS50297; ANK_REP_REGION; 3.
DR PROSITE; PS50088; ANK_REPEAT; 3.
DR PROSITE; PS52003; OCA; 1.
PE 4: Predicted;
KW ANK repeat {ECO:0000256|PROSITE-ProRule:PRU00023};
KW Reference proteome {ECO:0000313|Proteomes:UP000007648}.
FT DOMAIN 113..135
FT /note="OCA"
FT /evidence="ECO:0000259|PROSITE:PS52003"
FT REPEAT 503..535
FT /note="ANK"
FT /evidence="ECO:0000256|PROSITE-ProRule:PRU00023"
FT REPEAT 636..668
FT /note="ANK"
FT /evidence="ECO:0000256|PROSITE-ProRule:PRU00023"
FT REPEAT 672..708
FT /note="ANK"
FT /evidence="ECO:0000256|PROSITE-ProRule:PRU00023"
FT REGION 1..24
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 44..117
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 296..333
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 351..388
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 47..85
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 92..106
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ SEQUENCE 742 AA; 80570 MW; 376EB92AE890FE7E CRC64;
MIVDKLQEDG RGAEGLLDGA AGEGGLMTSP LNLAYFYGGS PPSAAVGASE ASFSSSGHST
PGSPGSDSSD FSSSSSVSAA SSCSAPGEPR SRGGSRADRA PGEHHMAGGR QQRGPFQGVR
VRNSVKELLL HIRNNKQKSA APAVEDFKAQ SVTTEPFTAE LKNILAHSGK RKGADAGSDG
PACKRPAVSL HTQFLTPPQT PTPVDSMEDV HINEPKQSNN SDLLQNIMNI KNESNPVSLN
TVQFSWMSPV VLNQSSPREQ YQDFHGGQTL TPPQKYQSFQ VSSSPQMMDQ SQIYQFSSPQ
SQDLQQPYGH ISVPECSPYA GKPPSPNYEP NLFDGQEMLF CSSQSFASLL NSPGEPENIA
LPIQTSPSAQ QQQQQQQQQQ QQQQQHRHSN EINIQNFNLG PSNPCDVLSG QDLGLTPLNV
SLPLQNVTGN SMNTTQLGKS FFQWQVEQEE NKLANLSQDH FLSKDADGDT LLHIAVAQGR
RALSYVLARK MSALQMLDIK EHNGQSAFQV AVAANQHLIV QDLVNLGAQV NTTDCWGRTP
LHVCAEKGHS QVLQAIQKGA ICSNQFIDLE ATNYDGLTAL HCAVVAHNAV VHELQRNQQH
HSPEVQELLL KNKSLVDTIK CLIQMGATVE AKDRKSGRTA LHLAAEEANL ELIRLFLELP
SCLSFVNAKA YNGNTALHVA ASLQYRVTQL DAVRLLMRKG ADPSTRNLEN EQPVHLVPDG
PVGEQIRRIL KGKSVQQRAP PY
//
